Acquisitions - Contingent Consideration (Details) $ in Millions	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Jul. 02, 2024 USD ($)
Business Combination [Line Items]
Contingent consideration obligations		$ 291.2
Contingent consideration obligations	$ 246.4	$ 221.6
Human Immunology Biosciences
Business Combination [Line Items]
Range of outcomes, value, high			$ 650.0
Contingent consideration obligations			485.1
Contingent consideration obligations			279.3
Contingent consideration obligations			$ 205.8
Human Immunology Biosciences | Measurement Input, Probability Rate
Business Combination [Line Items]
Discount rate			0.670
Human Immunology Biosciences | Minimum | Risk-adjusted discount rate
Business Combination [Line Items]
Discount rate			0.062
Human Immunology Biosciences | Minimum | Measurement Input, Probability Rate
Business Combination [Line Items]
Discount rate	0.700
Human Immunology Biosciences | Maximum | Phase 3 Clinical Trial, Felzartamab Two
Business Combination [Line Items]
Contingent consideration obligations			$ 150.0
Human Immunology Biosciences | Maximum | Phase 3 Clinical Trial, Felzartamab One
Business Combination [Line Items]
Contingent consideration obligations			$ 150.0
Human Immunology Biosciences | Maximum | Risk-adjusted discount rate
Business Combination [Line Items]
Discount rate			0.070
Human Immunology Biosciences | Maximum | Measurement Input, Probability Rate
Business Combination [Line Items]
Discount rate	0.950